CN110372714A - 山酮素骨架拼接螺环氧化吲哚类化合物及其制备方法及应用 - Google Patents

山酮素骨架拼接螺环氧化吲哚类化合物及其制备方法及应用 Download PDF

Info

Publication number
CN110372714A
CN110372714A CN201910740241.2A CN201910740241A CN110372714A CN 110372714 A CN110372714 A CN 110372714A CN 201910740241 A CN201910740241 A CN 201910740241A CN 110372714 A CN110372714 A CN 110372714A
Authority
CN
China
Prior art keywords
loop coil
indole compounds
mountain ketone
element skeleton
ketone element
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201910740241.2A
Other languages
English (en)
Other versions
CN110372714B (zh
Inventor
刘雄利
周彦佑
何学雯
常顺琴
周英
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guizhou University
Original Assignee
Guizhou University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guizhou University filed Critical Guizhou University
Priority to CN201910740241.2A priority Critical patent/CN110372714B/zh
Publication of CN110372714A publication Critical patent/CN110372714A/zh
Application granted granted Critical
Publication of CN110372714B publication Critical patent/CN110372714B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

本发明公开了一种山酮素骨架拼接螺环氧化吲哚类化合物，本发明以各种取代的双功能氧化吲哚‑色酮合成子1及各种取代的肉桂醛2在有机溶剂中，在有机小分子二级胺催化剂作用下，进行Michael/Michael环加成反应，获得山酮素骨架拼接螺环氧化吲哚类化合物3，该类化合物包含潜在的生物活性山酮素骨架和螺环氧化吲哚化合物骨架，可以为生物活性筛选提供化合物源，对药物的筛选和制药行业具有重要的应用价值。本发明操作简单易行，原料合成便宜易得，可以在各种有机溶剂中进行，也具有较好的空气稳定性，适用性广，对于各种取代基都有很好的兼容性。且该类骨架化合物对人白血病细胞(K562)具有肿瘤生长抑制活性作用。

Description

山酮素骨架拼接螺环氧化吲哚类化合物及其制备方法及应用
技术领域
本发明涉及化学技术和药学技术领域，尤其是一种山酮素骨架拼接螺环氧化吲哚类化合物及其制备方法及应用。
背景技术
根据药物设计的活性骨架拼接和迁越原理，把两个或多个具有生物活性骨架拼接成一个潜在生物活性的多骨架分子在有机化学和医药化学中是极其重要的研究领域。(1)螺六元碳环氧化吲哚广泛存在天然产物和合成药物分子中，吸引了许多化学工作者及医药化学团队的广泛关注，例如，天然产物或活性小分子螺六元碳环氧化吲哚Satavaptan和progesterone receptor agonist II表现明显的生物活性。(2)山酮素骨架也普遍存在天然产物和药物分子中。例如:天然产物分子Ergochrome DD，Diversonol，Desoxydiversonol，Applanatin B和Isocochlioquinone A共享一个山酮素分子单元，这些化合物在解除病痛、经济发展中起着重大作用。鉴于螺六元碳环氧化吲哚骨架和山酮素骨架具有潜在的生物活性。因此，把螺六元碳环氧化吲哚骨架拼接到山酮素骨架，合成一系列新的潜在多活性官能团的山酮素骨架拼接螺环氧化吲哚类化合物，可以为生物活性筛选提供化合物源，对药物的筛选和制药行业具有重要的应用价值(如图8所示)。
发明内容
本发明的目的是：提供一种山酮素骨架拼接螺环氧化吲哚类化合物及其制备方法与应用，它是一类重要的医药中间体类似物和药物分子类似物，对药物筛选和制药行业具有重要的应用价值，且其合成方法非常经济简便。
本发明还发现该类化合物在制备防治肿瘤疾病药物中的应用。
本发明是这样实现的：一种山酮素骨架拼接螺环氧化吲哚类化合物，该化合物具有如下通式(Ⅰ)的结构：
式中，R1为甲氧基或氯或氟或氢；R2为甲基或异丙基或氟或氢。
山酮素骨架拼接螺环氧化吲哚类化合物的制备方法，将各种取代的双功能氧化吲哚-色酮合成子1及各种取代的肉桂醛2在有机溶剂中，在有机小分子二级胺催化剂作用下，进行Michael/Michael环加成反应，获得山酮素骨架拼接螺环氧化吲哚类化合物3。
合成路线举例如下：
其中合成路线中的化合物，其取代基满足式中，R1为甲氧基或氯或氟或氢；R2为甲基或异丙基或氟或氢。
反应机理如下：
所述的有机溶剂为乙腈、甲苯、二氯甲烷、或氯仿。
所述的有机小分子碱性催化剂为有机小分子二级胺催化剂为二乙胺或吡咯或哌啶或手性脯氨酸或手性脯氨醇或手性二芳基脯氨醇硅醚。
有机小分子二级胺催化剂部分举例如下(但需强调的是本发明的有机小分子二级胺催化剂不限于如下表示的内容)：
所述的三级胺添加剂为DABCO或三乙胺或DBU。
各种取代的双功能氧化吲哚-色酮合成子及各种取代的肉桂醛在有机溶剂中的反应温度为-10℃至40℃，反应时间为2至10天。
山酮素骨架拼接螺环氧化吲哚类化合物在制备防治肿瘤疾病药物中的应用。
通过采用上述技术方案，以各种取代的双功能氧化吲哚-色酮合成子1及各种取代的肉桂醛2在有机溶剂中，在有机小分子二级胺催化剂作用下，进行Michael/Michael环加成反应，获得山酮素骨架拼接螺环氧化吲哚类化合物3，该类化合物包含潜在的生物活性山酮素骨架和螺环氧化吲哚化合物骨架，可以为生物活性筛选提供化合物源，对药物的筛选和制药行业具有重要的应用价值。且该骨架化合物对人白血病细胞(K562)具有抑制活性的作用。本发明操作简单易行，原料合成便宜易得，可以在各种有机溶剂中进行，也具有较好的空气稳定性，适用性广，对于各种取代基都有很好的兼容性。
附图说明
图1及图2为本发明的实施例的化合物3a谱图数据；
图3为化合物3a液相谱图数据；
图4及图5为本发明的实施例的化合物3b谱图数据；
图6为化合物3b液相谱图数据；
图7为本发明的实施例的化合物3h单晶图和圆二色谱(ECD)图；
图8为本发明所合成的化合物的设计思路及其创造性。
具体实施方式
本发明的实施例：在反应管中依次加入双功能氧化吲哚-色酮合成子1a(0.10mmol)，肉桂醛2a(0.15mmol)，手性二苯基脯氨醇硅醚C3(20mol％，0.02mmol)和1.0mL甲苯，室温中搅拌反应2天后,添加DABCO·6H2O(20mol％，0.02mmol),继续反应5天，TLC检测基本反应完全，直接上样经柱层析(洗脱剂：V(石油醚)：V(乙酸乙酯)＝4:1)纯化得化合物3a，白色固体，熔点：136.4-138.2℃；产率57％；95％ee,>20:1dr,[α]D 20＝+60.10(c 0.8,CH2Cl2)；The ee was determined by HPLC analysis using a Chiralpak IA column(90/10 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝15.04min；τminor＝34.08min)。核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.56(s,9H),1.96-2.03(m,1H),2.59-2.64(m,1H),3.23(d,J＝14.5Hz,1H),4.00-4.08(m,1H),4.64-4.75(m,2H),6.91-6.93(m,2H),6.96-7.07(m,5H),7.16-7.18(m,2H),7.27-7.30(m,1H),7.43-7.51(m,2H),7.86-7.89(m,1H),9.72(d,J＝3.0Hz,1H)；13C NMR(CDCl3,125MHz)δ:28.1,31.5,42.8,50.8,51.4,52.6,79.8,84.5,114.9,118.0,120.8,121.9,122.4,124.6,127.1,128.1,128.2,128.8,129.7,134.3,136.2,138.9,148.5,160.8,176.7,192.8,202.2；HRMS(ESI-TOF)m/z:Calcd.for C32H29NNaO6[M+Na]+:546.1887；Found:546.1893.
化合物3b至3u的制备方法同化合物3a，投料比与化合物3a相同，可得到化合物3b至3u，反应产率和dr值,ee值见表1和表2，但需强调的是本发明的化合物不限于表1和表2所表示的内容。
表1为一种山酮素骨架拼接螺环氧化吲哚类化合物的化学结构
表2为一种山酮素骨架拼接螺环氧化吲哚类化合物的化学结构
本实施例制备化合物3b:白色固体,熔点：108.2-109.9℃；产率54％；92％ee,>20:1dr,[α]D 20＝+60.42(c 2.1,CH2Cl2)；The ee was determined by HPLC analysis using aChiralpak IA column(70/30 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝10.59min；τminor＝23.92min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.57(s,9H),1.95-2.02(m,1H),2.59-2.64(m,1H),3.25(d,J＝15.0Hz,1H),3.98-4.05(m,1H),4.58-4.73(m,2H),6.69-6.73(m,2H),6.88-6.90(m,2H),6.96-6.98(m,1H),7.03-7.07(m,1H),7.17-7.20(m,2H),7.27-7.29(m,1H),7.46-7.51(m,2H),7.86-7.88(m,1H),9.74(d,J＝3.5Hz,1H)；13C NMR(CDCl3,125MHz)δ:28.0,31.3,42.7,49.6,51.3,52.6,79.7,84.6,115.0,115.1(d,JCF＝21.2Hz),117.8,120.6,122.1(d,JCF＝29.0Hz),124.6,127.0,128.9,129.4,130.2,136.1,138.8,148.3,160.6,161.6(d,JCF＝246.0Hz),176.5,192.5,201.9；HRMS(ESI-TOF)m/z:Calcd.for C32H28FNNaO6[M+Na]+:564.1793；Found:564.1798.
本实施例制备化合物3c:白色固体,熔点：119.8-120.9℃；产率55％；92％ee,>20:1dr,[α]D 20＝+40.84(c 1.8,CH2Cl2)；The ee was determined by HPLC analysis using aChiralpak IA column(70/30 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝11.40min；τminor＝24.21min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.58(s,9H),1.94-2.01(m,1H),2.59-2.64(m,1H),3.24(d,J＝15.0Hz,1H),3.97-4.04(m,1H),4.59-4.71(m,2H),6.80(d,J＝9.5Hz,2H),6.97(d,J＝10.0Hz,1H),7.03-7.07(m,1H),7.14-7.21(m,4H),7.27-7.29(m,1H),7.46-7.50(m,2H),7.86-7.88(m,1H),9.76(d,J＝2.5Hz,1H)；13C NMR(CDCl3,125MHz)δ:28.0,31.5,42.7,49.7,51.2,52.4,79.8,84.7,115.0,117.8,120.6,121.9,122.1,122.2,124.6,127.0,128.9,129.3,130.1,131.3,133.6,136.2,138.8,148.2,160.5,176.5,192.4,201.9；HRMS(ESI-TOF)m/z:Calcd.for C32H28BrNNaO6[M+Na]+:624.0992；Found:624.0993.
本实施例制备化合物3d:白色固体,熔点：102.5-104.1℃；产率57％；93％ee,>20:1dr,[α]D 20＝+140.40(c 2.2,CH2Cl2)；The ee was determined by HPLC analysis usinga Chiralpak IA column(70/30 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝7.42min；τminor＝12.21min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.51(s,9H),1.89-1.95(m,1H),2.25(s,3H),2.53-2.56(m,1H),3.17(d,J＝11.5Hz,1H),3.94-3.95(m,1H),4.60-4.62(m,2H),6.80-6.85(m,3H),6.95-6.99(m,3H),7.10-7.12(m,2H),7.19-7.25(m,2H),7.37-7.39(m,1H),7.60(s,1H),9.66(s,1H)；13C NMR(CDCl3,125MHz)δ:20.5,28.1,31.5,42.8,50.6,51.4,52.6,79.8,84.4,114.8,117.6,120.3,122.3,124.5,126.6,127.9,128.1,128.7,129.7,131.3,134.3,137.2,138.8,148.5,158.8,176.7,192.9,202.2；HRMS(ESI-TOF)m/z:Calcd.for C33H31NNaO6[M+Na]+:560.2044；Found:560.2047.
本实施例制备化合物3e:白色固体,熔点：114.1-115.9℃；产率57％；96％ee,>20:1dr,[α]D 20＝+60.02(c 1.2,CH2Cl2)；The ee was determined by HPLC analysis using aChiralpak IC column(90/10 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝16.78min；τminor＝21.36min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.51(s,9H),1.87-1.94(m,1H),2.25(s,3H),2.53-2.57(m,1H),3.19(d,J＝15.0Hz,1H),3.89-3.96(m,1H),4.51-4.62(m,2H),6.62-6.67(m,2H),6.79-6.83(m,3H),7.11-7.14(m,2H),7.21-7.25(m,2H),7.39-7.42(m,1H),7.59(s,1H),9.68(d,J＝3.0Hz,1H)；13C NMR(CDCl3,125MHz)δ:20.4,28.0,31.4,42.7,49.5,51.4,52.7,79.8,84.6,114.9(d,JCF＝21.4Hz),115.2,117.6,120.2,122.2,124.6,126.6,128.8,129.5,130.2,130.3,131.4,137.2,138.8,148.3,158.7,161.6(d,JCF＝246.2Hz),176.5,192.7,202.0；HRMS(ESI-TOF)m/z:Calcd.for C33H30FNNaO6[M+Na]+:578.1949；Found:578.1951.
本实施例制备化合物3f:白色固体,熔点：110.2-112.1℃；产率56％；91％ee,10:1dr,[α]D 20＝+170.33(c 2.2,CH2Cl2)；The ee was determined by HPLC analysis usinga Chiralpak IC column(90/10 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝18.90min；τminor＝24.60min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.52(s,9H),1.87-1.92(m,1H),2.53-2.56(m,1H),3.18(d,J＝11.5Hz,1H),3.90-3.92(m,1H),4.56-4.58(m,2H),6.72-6.74(m,2H),6.81(d,J＝8.5Hz,1H),7.07-7.13(m,4H),7.19-7.25(m,2H),7.41(d,J＝7.0Hz,1H),7.59(s,1H),9.69(s,1H)；13C NMR(CDCl3,125MHz)δ:20.5,28.1,31.6,42.8,49.6,51.2,52.5,79.9,84.7,115.0,117.6,120.3,122.1,122.2,124.7,126.6,129.0,129.4,130.2,131.3,131.5,133.7,137.3,138.8,148.3,158.7,176.5,192.7,202.0；HRMS(ESI-TOF)m/z:Calcd.for C33H30BrNNaO6[M+Na]+:638.1149；Found:638.1155.
本实施例制备化合物3g:白色固体,熔点：128.4-129.7℃；产率42％；93％ee,>20:1dr,[α]D 20＝+27.98(c 0.34,CH2Cl2)；The ee was determined by HPLC analysis usinga Chiralpak IA column(95/5 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝16.22min；τminor＝36.25min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.23(s,3H),1.25(s,3H),1.57(s,9H),1.95-2.02(m,1H),2.61-2.66(m,1H),2.86-2.93(m,1H),3.24(d,J＝14.5Hz,1H),3.99-4.06(m,1H),4.66-4.73(m,2H),6.90-6.96(m,3H),7.00-7.08(m,3H),7.17-7.19(m,2H),7.29-7.31(m,1H),7.37-7.40(m,1H),7.44-7.46(m,1H),7.73(s,1H),9.73(s,1H)；13C NMR(CDCl3,125MHz)δ:24.0,28.2,31.6,33.4,42.9,50.7,51.4,52.6,79.9,84.5,114.9,117.8,120.4,122.4,124.1,124.6,128.0,128.2,128.8,129.7,134.4,135.0,138.9,142.5,148.6,159.1,176.8,193.1,202.4；HRMS(ESI-TOF)m/z:Calcd.for C35H35NNaO6[M+Na]+:588.2357；Found:588.2362.
本实施例制备化合物3h:白色固体,熔点：129.7-131.6℃；产率40％；98％ee,>20:1dr,[α]D 20＝+40.80(c 0.60,CH2Cl2)；The ee was determined by HPLC analysis usinga Chiralpak IA column(95/5 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝16.92min；τminor＝38.81min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.22(s,3H),1.24(s,3H),1.58(s,9H),1.93-2.00(m,1H),2.60-2.65(m,1H),2.86-2.93(m,1H),3.25(d,J＝14.5Hz,1H),3.96-4.02(m,1H),4.58-4.68(m,2H),6.80(d,J＝9.5Hz,2H),6.91(d,J＝10.5Hz,1H),7.14-7.21(m,4H),7.28-7.30(m,1H),7.37-7.40(m,1H),7.46-7.49(m,1H),7.72(d,J＝3.0Hz,1H),9.76(d,J＝2.0Hz,1H)；13C NMR(CDCl3,125MHz)δ:24.0,28.1,31.6,33.4,42.8,49.7,51.3,52.6,80.0,84.8,115.1,117.8,120.4,122.1,122.3,124.1,124.8,129.0,129.4,130.3,131.4,133.8,135.0,138.9,142.6,148.4,159.0,176.6,192.9,202.2；HRMS(ESI-TOF)m/z:Calcd.for C35H34BrNNaO6[M+Na]+:666.1462；Found:666.1467.
本实施例制备化合物3i:白色固体,熔点：101.9-103.3℃；产率52％；96％ee,>20:1dr,[α]D 20＝+80.42(c 1.5,CH2Cl2)；The ee was determined by HPLC analysis using aChiralpak IC column(90/10 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝15.60min；τminor＝20.28min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.50(s,9H),1.89-1.96(m,1H),2.53-2.57(m,1H),3.15(d,J＝15.0Hz,1H),3.93-4.00(m,1H),4.56-4.68(m,2H),6.85-6.91(m,3H),6.93-7.02(m,3H),7.10-7.16(m,3H),7.20-7.23(m,1H),7.37-7.39(m,1H),7.44-7.47(m,1H),9.64(d,J＝2.5Hz,1H)；13CNMR(CDCl3,125MHz)δ:28.0,31.3,42.7,50.7,51.2,52.4,79.8,84.4,112.0(d,JCF＝23.1Hz),114.8,119.5,119.6,121.1,122.2,123.6(d,JCF＝24.2Hz),124.5,128.0,128.2,128.8,129.4,134.0,138.8,148.4,156.2,157.5(d,JCF＝213.8Hz),176.6,201.9；HRMS(ESI-TOF)m/z:Calcd.for C32H28FNNaO6[M+Na]+:564.1793；Found:564.1798.
本实施例制备化合物3j:白色固体,熔点：122.1-123.2℃；产率56％；95％ee,>20:1dr,[α]D 20＝+50.35(c 1.6,CH2Cl2)；The ee was determined by HPLC analysis using aChiralpak IC column(90/10 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝14.80min；τminor＝18.01min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.51(s,9H),1.87-1.94(m,1H),2.53-2.58(m,1H),3.16(d,J＝15.0Hz,1H),3.91-3.98(m,1H),4.52-4.65(m,2H),6.63-6.67(m,2H),6.83-6.85(m,2H),6.88-6.91(m,1H),7.12-7.16(m,3H),7.19-7.22(m,2H),7.40-7.42(m,1H),7.44-7.47(m,1H),9.66(d,J＝2.5Hz,1H)；13C NMR(CDCl3,125MHz)δ:28.0,31.2,42.6,49.7,51.3,52.5,79.9,84.7,112.0(d,JCF＝24.0Hz),115.0(d,JCF＝20.4Hz),115.2(d,JCF＝22.7Hz),119.5,119.6,122.2,123.6(d,JCF＝25.0Hz),124.6,128.9,129.2,138.8,148.3,156.2,157.4(d,JCF＝241.0Hz),162.2(d,JCF＝246.2Hz),176.5,191.8,201.7；HRMS(ESI-TOF)m/z:Calcd.forC32H27F2NNaO6[M+Na]+:582.1699；Found:582.1704.
本实施例制备化合物3k:白色固体,熔点：92.3-93.4℃；产率62％；96％ee,>20:1dr,[α]D 20＝+30.62(c 2.8,CH2Cl2)；The ee was determined by HPLC analysis using aChiralpak IC column(90/10 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝15.72min；τminor＝20.37min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.63(s,9H),1.99-2.04(m,1H),2.64-2.68(m,1H),3.27(d,J＝12.0Hz,1H),4.01-4.07(m,1H),4.64-4.75(m,2H),6.85-6.86(m,2H),6.99-7.02(m,1H),7.20(d,J＝8.0Hz,2H),7.23-7.29(m,3H),7.31-7.33(m,1H),7.52-7.57(m,2H),9.78(d,J＝2.0Hz,1H)；13C NMR(CDCl3,125MHz)δ:28.0,31.4,42.6,49.7,51.1,52.3,80.0,84.8,112.0,112.2,115.1,119.5,119.6,121.1,122.1(d,JCF＝23.8Hz),123.7(d,JCF＝25.1Hz),124.7,129.0,129.1,131.3,133.4,138.8,148.2,156.8,157.5(d,JCF＝241.3Hz),176.5,191.7,201.7；HRMS(ESI-TOF)m/z:Calcd.for C32H27BrFNNaO6[M+Na]+:642.0898；Found:642.0893.
本实施例制备化合物3l:白色固体,熔点：133.5-135.1℃；产率60％；92％ee,>20:1dr,[α]D 20＝+50.05(c 1.4,CH2Cl2)；The ee was determined by HPLC analysis using aChiralpak IC column(90/10 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝16.27min；τminor＝32.42min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.50(s,9H),1.85-1.90(m,1H),2.54-2.58(m,1H),3.12(d,J＝11.5Hz,1H),3.92-3.98(m,1H),4.55-4.66(m,2H),6.79-6.82(m,1H),6.87-6.89(m,3H),6.95-7.02(m,4H),7.14-7.17(m,1H),7.37-7.40(m,1H),7.44-7.46(m,1H),9.63(s,1H)；13C NMR(CDCl3,125MHz)δ:28.1,31.4,42.7,50.7,51.7,52.5,79.7,84.7,110.0(d,JCF＝24.2Hz),115.4(d,JCF＝22.4Hz),116.4,118.0,120.7,122.0,127.1,128.3,128.4,131.6,134.1,134.7,136.3,148.5,159.5(d,JCF＝246.1Hz),160.7,161.1,176.2,192.6,201.9；HRMS(ESI-TOF)m/z:Calcd.for C32H28FNNaO6[M+Na]+:564.1793；Found:564.1797.
本实施例制备化合物3m:白色固体,熔点：114.8-116.2℃；产率59％；95％ee,>20:1dr,[α]D 20＝+50.71(c 0.80,CH2Cl2)；The ee was determined by HPLC analysis usinga Chiralpak IC column(90/10 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝13.93min；τminor＝29.65min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.58(s,9H),1.90-1.97(m,1H),2.61-2.66(m,1H),3.22(d,J＝15.0Hz,1H),3.97-4.05(m,1H),4.60-4.71(m,2H),6.73-6.78(m,2H),6.88-7.09(m,6H),7.47-7.53(m,2H),7.87-7.89(m,1H),9.75(d,J＝3.0Hz,1H)；13C NMR(CDCl3,125MHz)δ:28.0,31.3,42.6,49.6,51.6,52.6,79.7,84.8,109.8(d,JCF＝25.4Hz),115.3(d,JCF＝22.3Hz),115.5(d,JCF＝23.1Hz),116.4(d,JCF＝8.1Hz),116.5,117.8,120.6,122.0,127.1,130.0,134.7,136.2,148.2,158.5,159.8(d,JCF＝214.3Hz),160.5,161.3,161.7(d,JCF＝245.0Hz),176.1,192.3,201.7；HRMS(ESI-TOF)m/z:Calcd.for C32H27F2NNaO6[M+Na]+:582.1699；Found:582.17004.
本实施例制备化合物3n:白色固体,熔点：105.1-106.8℃；产率56％；>99％ee,9:1dr,[α]D 20＝+210.10(c 2.30,CH2Cl2)；The ee was determined by HPLC analysis usinga Chiralpak IC column(90/10 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝18.00min；τminor＝24.41min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.61(s,9H),1.94-1.98(m,1H),2.64-2.67(m,1H),3.24(d,J＝10.0Hz,1H),4.00-4.05(m,1H),4.62-4.72(m,2H),6.86-6.87(m,2H),6.92-6.96(m,1H),7.00(d,J＝7.0Hz,1H),7.04-7.06(m,1H),7.08-7.10(m,1H),7.22(d,J＝7.0Hz,2H),7.51-7.55(m,2H),7.89-7.91(m,1H),9.78(s,1H)；13C NMR(CDCl3,125MHz)δ:28.1,31.5,42.6,49.6,51.5,52.4,79.7,85.0,109.8(d,JCF＝20.0Hz),115.6(d,JCF＝20.5Hz),116.6,117.9,120.6,122.0,122.3,127.1,131.5,132.4,133.4,134.7,136.3,148.2,160.0(d,JCF＝202.5Hz),160.5,176.0,192.2,201.6；HRMS(ESI-TOF)m/z:Calcd.for C32H27BrFNNaO6[M+Na]+:642.0898；Found:642.0895.
本实施例制备化合物3o:白色固体,熔点：116.6-118.2℃；产率55％；92％ee,>20:1dr,[α]D 20＝+70.14(c 3.3,CH2Cl2)；The ee was determined by HPLC analysis using aChiralpak IC column(90/10 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝12.76min；τminor＝17.61min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.50(s,9H),1.85-1.90(m,1H),2.54-2.58(m,1H),3.12(d,J＝11.5Hz,1H),3.92-3.98(m,1H),4.55-4.66(m,2H),6.79-6.82(m,1H),6.87-6.89(m,3H),6.95-7.02(m,4H),7.14-7.17(m,1H),7.37-7.40(m,1H),7.44-7.46(m,1H),9.63(s,1H)；13C NMR(CDCl3,125MHz)δ:28.0,31.2,42.6,50.7,51.5,52.3,79.8,84.7,109.8(d,JCF＝25.0Hz),112.1(d,JCF＝23.8Hz),115.4(d,JCF＝22.5Hz),116.3,116.4,119.5,119.6,121.1,123.7(d,JCF＝25.1Hz),128.2,128.4,133.8,148.3,156.9,157.5(d,JCF＝241.3Hz),159.9(d,JCF＝242.5Hz),176.2,191.8,201.6；HRMS(ESI-TOF)m/z:Calcd.for C32H27F2NNaO6[M+Na]+:582.1699；Found:582.17004.
本实施例制备化合物3p:白色固体,熔点：109.3-110.7℃；产率56％；93％ee,>20:1dr,[α]D 20＝+20.61(c 1.2,CH2Cl2)；The ee was determined by HPLC analysis using aChiralpak IC column(90/10 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝13.53min；τminor＝17.95min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.51(s,9H),1.82-1.89(m,1H),2.54-2.58(m,1H),3.14(d,J＝15.0Hz,1H),3.89-3.97(m,1H),4.50-4.63(m,2H),6.67-6.71(m,2H),6.81-6.91(m,4H),6.93-6.96(m,1H),7.14-7.18(m,1H),7.40-7.47(m,2H),9.65(d,J＝3.0Hz,1H)；13C NMR(CDCl3,125MHz)δ:28.0,31.2,42.5,49.6,51.5,52.4,79.8,84.9,109.7(d,JCF＝24.2Hz),112.1(d,JCF＝23.4Hz),115.3(d,JCF＝22.5Hz),115.6(d,JCF＝20.1Hz),116.4,116.5,119.5,119.6,121.1,123.7(d,JCF＝24.4Hz),129.8,148.2,157.7(d,JCF＝245.1Hz),159.6(d,JCF＝225.4Hz),162.3(d,JCF＝228.3Hz),176.1,191.6,201.5；HRMS(ESI-TOF)m/z:Calcd.forC32H26F3NNaO6[M+Na]+:600.1604；Found:600.1598.
本实施例制备化合物3q:白色固体,熔点：102.8-104.2℃；产率58％；97％ee,15:1dr,[α]D 20＝+40.74(c 2.00,CH2Cl2)；The ee was determined by HPLC analysis usinga Chiralpak IC column(90/10 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝15.24min；τminor＝19.73min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.52(s,9H),1.83-1.88(m,1H),2.54-2.57(m,1H),3.12(d,J＝11.5Hz,1H),3.89-3.94(m,1H),4.52-4.61(m,2H),6.76-6.78(m,2H),6.84-6.95(m,3H),7.12-7.19(m,3H),7.41-7.46(m,2H),9.67(s,1H)；13C NMR(CDCl3,125MHz)δ:28.1,31.4,42.6,49.7,51.4,52.3,79.9,85.0,109.8(d,JCF＝25.1Hz),112.2(d,JCF＝22.5Hz),115.7(d,JCF＝22.5Hz),116.6,116.7,119.6,122.4,123.8(d,JCF＝25.4Hz),131.6,133.2,134.7,148.2,156.8,157.5(d,JCF＝241.3Hz),160.0(d,JCF＝243.8Hz),176.0,191.5,201.4；HRMS(ESI-TOF)m/z:Calcd.for C32H26BrF2NNaO6[M+Na]+:660.0804；Found:660.0810.
本实施例制备化合物3r:白色固体,熔点：118.7-120.0℃；产率47％；94％ee,>20:1dr,[α]D 20＝+45.03(c 0.25,CH2Cl2)；The ee was determined by HPLC analysis usinga Chiralpak IA column(93/7 hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝30.52min；τminor＝68.61min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.58(s,9H),1.93-2.00(m,1H),2.58-2.63(m,1H),3.20(d,J＝14.5Hz,1H),3.98-4.05(m,1H),4.65-4.74(m,2H),6.93-6.94(m,2H),6.98(d,J＝10.5Hz,1H),7.04-7.11(m,4H),7.17-7.23(m,2H),7.48-7.54(m,2H),7.87-7.89(m,1H),9.73(d,J＝2.5Hz,1H)；13C NMR(CDCl3,125MHz)δ:28.1,31.5,42.7,50.6,51.3,52.5,79.7,85.1,115.7,118.0,120.7,122.0,123.3,124.7,127.1,128.2,128.3,128.4,128.5,129.1,134.1,134.5,136.3,139.8,148.3,160.7,176.2,192.7,202.1；HRMS(ESI-TOF)m/z:Calcd.forC32H28ClNNaO6[M+Na]+:580.1497；Found:580.1501.
本实施例制备化合物3s:白色固体,熔点：132.4-133.6℃；产率56％；93％ee,>20:1dr；The ee was determined by HPLC analysis using a Chiralpak IA column(95/5hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝31.69min；τminor＝73.49min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.51(s,9H),1.84-1.91(m,1H),2.50-2.55(m,1H),3.16(d,J＝14.5Hz,1H),3.87-3.94(m,1H),4.50-4.62(m,2H),6.74(d,J＝10.0Hz,1H),6.89(d,J＝10.5Hz,1H),6.96-7.00(m,1H),7.09-7.15(m,4H),7.40-7.45(m,1H),7.50(s,1H),7.78-7.80(m,1H),9.68(s,1H)；13C NMR(CDCl3,125MHz)δ:27.0,30.5,41.6,48.5,50.0,51.4,78.7,84.2,114.8,116.8,119.6,121.0,121.3,122.1,123.7,126.0,126.8,129.1,130.5,132.4,133.6,135.2,138.6,147.0,159.5,174.9,191.2,200.6；HRMS(ESI-TOF)m/z:Calcd.for C32H27BrClNNaO6[M+Na]+:658.0602；Found:658.0607.
本实施例制备化合物3t:白色固体,熔点：98.5-99.7℃；产率34％；94％ee,>20:1dr；The ee was determined by HPLC analysis using a Chiralpak IC column(95/5hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝57.04min；τminor＝74.99min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.50(s,9H),1.87-1.93(m,1H),2.53-2.58(m,1H),3.15(d,J＝14.5Hz,1H),3.76(s,3H),3.94-4.01(m,1H),4.60-4.69(m,2H),6.61-6.64(m,1H),6.77(d,J＝3.0Hz,1H),6.88-6.92(m,3H),6.95-7.01(m,4H),7.31(d,J＝11.0Hz,1H),7.41-7.45(m,1H),7.80-7.82(m,1H),9.67(d,J＝2.5Hz,1H)；13CNMR(CDCl3,125MHz)δ:27.1,28.7,41.7,49.6,50.6,51.5,54.7,78.7,83.2,107.4,112.5,114.8,116.8,119.7,120.8,126.0,127.0,127.2,127.5,129.9,131.2,133.2,135.1,147.5,156.0,159.7,175.6,191.7,201.2；HRMS(ESI-TOF)m/z:Calcd.for C33H31NNaO7[M+Na]+:576.1993；Found:576.1989.
本实施例制备化合物3u:白色固体,熔点：93.7-94.9℃；产率41％；97％ee,>20:1dr；The ee was determined by HPLC analysis using a Chiralpak IC column(95/5hexane/i-PrOH；flow rate:1.0mL/min；λ＝254nm；τmajor＝62.24min；τminor＝76.19min)；核磁共振和高分辨质谱测试等结果如下：1H NMR(CDCl3,500MHz)δ:1.51(s,9H),1.84-1.91(m,1H),2.52-2.57(m,1H),3.15(d,J＝15.0Hz,1H),3.75(s,3H),3.90-3.97(m,1H),4.53-4.64(m,2H),6.64-6.67(m,1H),6.75-6.78(m,3H),6.91(d,J＝10.0Hz,1H),6.95-7.01(m,1H),7.11(d,J＝11.0Hz,2H),7.33(d,J＝11.0Hz,1H),7.41-7.45(m,1H),7.80-7.82(m,1H),9.69(d,J＝3.0Hz,1H)；13C NMR(CDCl3,125MHz)δ:27.0,30.5,41.7,48.7,50.4,51.5,54.7,78.8,83.5,107.5,112.6,115.1,116.8,119.7,120.9,121.1,126.0,129.1,129.6,130.3,131.1,132.6,135.2,147.3,156.0,159.6,175.5,191.4,200.9；HRMS(ESI-TOF)m/z:Calcd.for C33H30BrNNaO7[M+Na]+:654.1098；Found:654.11002.
本发明的式(1)化合物具有重要的生物活性，体外对人白血病细胞(K562)肿瘤细胞的细胞毒性试验表明：此类式(1)所示结构的山酮素骨架拼接螺环氧化吲哚类化合物对肿瘤细胞生长具有抑制作用，有可能发展成为新的防治肿瘤药物。但需强调的是本发明的化合物不限于人白血病细胞(K562)表示的细胞毒性。
药理实施例：化合物3m,3n,3p和3q对K562细胞的细胞毒性
K562(人慢性髓系白血病细胞)用RPMI-1640培养基培养，培养基中含10％的胎牛血清，100U/mL的青霉素和100U/mL链霉素。细胞以每孔5000个细胞的浓度加入到96孔中，在37℃含5％CO2潮湿空气的培养箱中培养24小时。
细胞存活率的测定用改良MTT法。细胞经过24小时的孵育后，分别将新配的化合物3m,3n,3p和3q的二甲基亚砜溶液以浓度梯度加入到各孔中，使孔中化合物最终浓度分别为5μmol/L,10μmol/L,20μmol/L,40μmol/L和80μmol/L。48小时后，每孔加入10μL MTT(5mg/mL)的磷酸盐缓冲液，再继续在37℃培养4小时后，离心5分钟除去未转化的MTT，每孔中加入150μL二甲基亚砜。以溶解还原的MTT晶体甲臜(formazan)，用酶标仪在490nm波长测定OD值。其中化合物3m,3n,3p和3q对K562细胞半抑制浓度IC50由spss软件(19版本)分析得到。化合物3m对K562肿瘤细胞的IC50为27.1μmol/L；化合物3n对K562肿瘤细胞的IC50为32.7μmol/L；化合物3p对K562肿瘤细胞的IC50为24.8μmol/L；化合物3q对K562肿瘤细胞的IC50为30.1μmol/L；而阳性对照顺铂对K562肿瘤细胞的IC50为20.5μmol/L。
实验结论：K562细胞是测试化合物对肿瘤细胞的细胞毒性的有效工具和评价指标。本实验表明此类式(1)所示的山酮素骨架拼接螺环氧化吲哚类化合物对K562细胞具有较强的细胞毒性，有可能发展成新的具有抗肿瘤作用的药物，值得继续深入研究下去。

Claims (7)

1.一种山酮素骨架拼接螺环氧化吲哚类化合物，其特征在于：该化合物具有如通式(Ⅰ)所示的结构：
式中，R1为甲氧基、氯、氟或氢；R2为甲基、异丙基、氟或氢。
2.一种如权利要求1所述的山酮素骨架拼接螺环氧化吲哚类化合物的制备方法，其特征在于：将各种取代的双功能氧化吲哚-色酮合成子及各种取代的肉桂醛在有机溶剂中，在有机小分子二级胺催化剂和三级胺添加剂的作用下，进行Michael/Michael环加成反应，获得山酮素骨架拼接螺环氧化吲哚类化合物。
3.根据权利要求2所述的山酮素骨架拼接螺环氧化吲哚类化合物的制备方法，其特征在于：所述的有机溶剂为乙腈、甲苯、二氯甲烷或氯仿。
4.根据权利要求2所述的山酮素骨架拼接螺环氧化吲哚类化合物的制备方法，其特征在于：所述的有机小分子二级胺催化剂为二乙胺、吡咯、哌啶、手性脯氨酸、手性脯氨醇或手性二芳基脯氨醇硅醚。
5.根据权利要求2所述的山酮素骨架拼接螺环氧化吲哚类化合物的制备方法，其特征在于：所述的三级胺添加剂为DABCO或三乙胺或DBU。
6.根据权利要求2所述的山酮素骨架拼接螺环氧化吲哚类化合物的制备方法，其特征在于：各种取代的双功能氧化吲哚-色酮合成子及各种取代的肉桂醛在有机溶剂中的反应温度为-10-40℃，反应时间为2-10天。
7.一种如权利要求1所述的山酮素骨架拼接螺环氧化吲哚类化合物在制备防治肿瘤疾病药物中的应用。
CN201910740241.2A 2019-08-12 2019-08-12 山酮素骨架拼接螺环氧化吲哚类化合物及其制备方法及应用 Active CN110372714B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910740241.2A CN110372714B (zh) 2019-08-12 2019-08-12 山酮素骨架拼接螺环氧化吲哚类化合物及其制备方法及应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910740241.2A CN110372714B (zh) 2019-08-12 2019-08-12 山酮素骨架拼接螺环氧化吲哚类化合物及其制备方法及应用

Publications (2)

Publication Number Publication Date
CN110372714A true CN110372714A (zh) 2019-10-25
CN110372714B CN110372714B (zh) 2022-03-15

Family

ID=68259023

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910740241.2A Active CN110372714B (zh) 2019-08-12 2019-08-12 山酮素骨架拼接螺环氧化吲哚类化合物及其制备方法及应用

Country Status (1)

Country Link
CN (1) CN110372714B (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111808113A (zh) * 2020-07-14 2020-10-23 贵州大学 六氢山酮素拼接螺环氧化吲哚骨架与酮酯基团类化合物及其制备方法及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110092793A (zh) * 2019-02-28 2019-08-06 贵州大学 山酮素骨架和异噁唑螺环氧化吲哚拼接衍生物及其制备方法及应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110092793A (zh) * 2019-02-28 2019-08-06 贵州大学 山酮素骨架和异噁唑螺环氧化吲哚拼接衍生物及其制备方法及应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NEELAKANDAN VIDHYA LAKSHMI: "An expedient approach for the synthesis of dispiropyrrolidine bisoxindoles,spiropyrrolidine oxindoles and spiroindane-1,3-diones through 1,3-dipolar cycloaddition reactions", 《TETRAHEDRON LETTERS》 *
XIONG ZUO: "Organocatalytic Reaction of Chromone-Oxindole Synthon: Access to Chromanone-Based Spirocyclohexaneoxindoles with Five Adjacent Stereocenters", 《J. ORG. CHEM.》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111808113A (zh) * 2020-07-14 2020-10-23 贵州大学 六氢山酮素拼接螺环氧化吲哚骨架与酮酯基团类化合物及其制备方法及应用
CN111808113B (zh) * 2020-07-14 2022-06-21 贵州大学 六氢山酮素拼接螺环氧化吲哚骨架与酮酯基团类化合物及其制备方法及应用

Also Published As

Publication number Publication date
CN110372714B (zh) 2022-03-15

Similar Documents

Publication Publication Date Title
FI91528C (fi) Optisesti aktiivisia alkyyliaryyliketaaleita ja menetelmä niiden valmistamiseksi
EP0666250B1 (fr) Dérivés de N-(3-aminopropyl)-N-phényl-5,6,7,8-tétrahydronaphtalène-2-carboxamide ayant des propriétés neuroprotectrices et anti-ischémiques, leur préparation et leur application en thérapeutique
JP7209897B2 (ja) Ｃｒｂｎタンパク質モジュレーターとしての二環式化合物
CN111875612B (zh) 色满酮拼接吡咯螺环氧化吲哚骨架与三氟甲基类化合物及其制备方法及应用
CN112390804B (zh) 环戊烷并色满酮拼接螺环氧化吲哚类化合物及其制备方法及应用
CN110372714A (zh) 山酮素骨架拼接螺环氧化吲哚类化合物及其制备方法及应用
CN107383030A (zh) 姜黄酮拼接3,3’‑吡咯双螺环氧化吲哚化合物及其制备方法及应用
CN109705130B (zh) 二氢色原酮骨架拼接多环吡咯螺环氧化吲哚化合物及其制备方法及应用
CN109776556A (zh) 吡唑啉酮山酮素骨架拼接氧化吲哚或苯并呋喃酮类化合物及其制备方法及应用
CN109970753A (zh) 山酮素骨架拼接氧化吲哚或苯并呋喃酮类化合物及其制备方法及应用
RU2045530C1 (ru) (+)форма 7,8-дигидро-6,6- диметил-7- окси-8-амино -6н-пирано(2,3-f) бенз-2,1,3 -оксадиазола, показывающая правое вращение в этаноле
CN110092793B (zh) 山酮素骨架和异噁唑螺环氧化吲哚拼接衍生物及其制备方法及应用
CN111808113B (zh) 六氢山酮素拼接螺环氧化吲哚骨架与酮酯基团类化合物及其制备方法及应用
CN109796471B (zh) 吲哚酮螺环丙烷螺-噻唑酮或螺-四氢噻唑酮类衍生物及其制备方法和应用
Meuer et al. Novel family of heterocyclic strained helixes. Cesium-assisted syntheses, conformational and chiroptical properties and geometries
ES2930284T3 (es) Método para preparar un compuesto de fenilalanina
CN110028519A (zh) 山酮素骨架拼接双螺环氧化吲哚化合物及其制备方法及应用
Bálint et al. Resolution of α-phenylethylamine by its acidic derivatives
CN110684032B (zh) 山酮素异恶唑骨架拼接吡唑啉酮或苯并呋喃酮类化合物及其制备方法及应用
CN109776555B (zh) 山酮素骨架拼接异噁唑与双螺环氧化吲哚衍生物及其制备方法及应用
CN106117234B (zh) Morusin骨架拼接convolutamydine A骨架类化合物及其制备方法及应用
CN110452230A (zh) 一种色原酮吡唑啉酮骨架拼接二氢查尔酮类化合物及其制备方法及应用
EP0285175B1 (en) Asymmetric photochemical reaction process
KR100208814B1 (ko) 알파토코페롤 4-아미노벤조산 에스테르 화합물 및 이의 제조방법
US4190651A (en) Cyclic phosphoric acid amide esters, and an insecticide containing the same as active ingredient

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant